Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Glaucoma surgery checked 5 years later: does it hold up?

NCT ID NCT07480343

Knowledge-focused Sponsor: Iantrek, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study follows 250 people with open-angle glaucoma who had a new type of surgery called CycloPen, which aims to improve fluid drainage from the eye. Researchers will measure eye pressure at 3, 4, and 5 years after surgery to see if the benefits last. The goal is to understand how well this procedure controls glaucoma over the long term.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that the CycloPen surgery provides lasting pressure control for glaucoma patients, potentially reducing the need for daily eye drops.
What could go wrong
This is an observational follow-up, not a new treatment test. It only includes patients who already did well initially, so results may not apply to everyone with glaucoma.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants are undergoing treatment for glaucoma at medical clinics located in the United States

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of open-angle glaucoma (OAG) in the study eye(s), including pigmentary and pseudoexfoliative glaucoma, at the time of CREST enrollment 2. Completed participation in CREST 3. Provide signed written consent using the Institutional Review Board (IRB)/Ethics Committee (EC) approved study-specific informed consent form (ICF) 4. Ability, comprehension, and willingness to follow study instructions Exclusion Criteria: 1. Systemic disease that, in the opinion of the Investigator, would put participant's health at risk and/or prevent completion of required study visits 2. Early termination from CREST 3. Secondary surgical intervention for long-term IOP control in the study eye(s)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Open-angle glaucoma (OAG) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Open-angle glaucoma (OAG)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CREST-XT Site 01

    Fort Washington, Pennsylvania, 19034, United States

  • CREST-XT Site 03

    Cape Coral, Florida, 33904, United States

  • CREST-XT Site 04

    Crossville, Tennessee, 38555, United States

  • CREST-XT Site 05

    Newport Beach, California, 92663, United States

  • CREST-XT Site 07

    Atlanta, Georgia, 30342, United States

  • CREST-XT Site 10

    DeLand, Florida, 32720, United States

  • CREST-XT Site 11

    Salt Lake City, Utah, 84132, United States

  • CREST-XT Site 12

    Chevy Chase, Maryland, 20815, United States

  • CREST-XT Site 13

    Rockville, Maryland, 20852, United States

  • CREST-XT Site 16

    Las Vegas, Nevada, 89145, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.